IMMUNE NETWORK

  • 제23권6호
  • /
  • Pages.43.1-43.10
  • /
  • 2023
  • /
  • 1598-2629(pISSN)
  • /
  • 2092-6685(eISSN)
대한면역학회 (The Korean Association of Immunobiologists)
권호 표지
DOI QR코드

DOI QR Code

Low Neutralizing Activities to the Omicron Subvariants BN.1 and XBB.1.5 of Sera From the Individuals Vaccinated With a BA.4/5-Containing Bivalent mRNA Vaccine

  • Eliel Nham (Division of Infectious Diseases, Department of Internal Medicine, Korea University Guro Hospital, Korea University College of Medicine) ;
  • Jineui Kim (Department of Microbiology, Vaccine Innovation Center, Korea University College of Medicine) ;
  • Jungmin Lee (Department of Microbiology, Vaccine Innovation Center, Korea University College of Medicine) ;
  • Heedo Park (Department of Microbiology, Vaccine Innovation Center, Korea University College of Medicine) ;
  • Jeonghun Kim (Department of Microbiology, Vaccine Innovation Center, Korea University College of Medicine) ;
  • Sohyun Lee (Department of Microbiology, Vaccine Innovation Center, Korea University College of Medicine) ;
  • Jaeuk Choi (Department of Microbiology, Vaccine Innovation Center, Korea University College of Medicine) ;
  • Kyung Taek Kim (Department of Microbiology, Vaccine Innovation Center, Korea University College of Medicine) ;
  • Jin Gu Yoon (Division of Infectious Diseases, Department of Internal Medicine, Korea University Guro Hospital, Korea University College of Medicine) ;
  • Soon Young Hwang (Department of Biostatistics, Korea University College of Medicine) ;
  • Joon Young Song (Division of Infectious Diseases, Department of Internal Medicine, Korea University Guro Hospital, Korea University College of Medicine) ;
  • Hee Jin Cheong (Division of Infectious Diseases, Department of Internal Medicine, Korea University Guro Hospital, Korea University College of Medicine) ;
  • Woo Joo Kim (Division of Infectious Diseases, Department of Internal Medicine, Korea University Guro Hospital, Korea University College of Medicine) ;
  • Man-Seong Park (Department of Microbiology, Vaccine Innovation Center, Korea University College of Medicine) ;
  • Ji Yun Noh (Division of Infectious Diseases, Department of Internal Medicine, Korea University Guro Hospital, Korea University College of Medicine)
  • 투고 : 2023.08.04
  • 심사 : 2023.10.30
  • 발행 : 2023.12.31
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

The continuous emergence of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) variants has provided insights for updating current coronavirus disease 2019 (COVID-19) vaccines. We examined the neutralizing activity of Abs induced by a BA.4/5-containing bivalent mRNA vaccine against Omicron subvariants BN.1 and XBB.1.5. We recruited 40 individuals who had received a monovalent COVID-19 booster dose after a primary series of COVID-19 vaccinations and will be vaccinated with a BA.4/5-containing bivalent vaccine. Sera were collected before vaccination, one month after, and three months after a bivalent booster. Neutralizing Ab (nAb) titers were measured against ancestral SARS-CoV-2 and Omicron subvariants BA.5, BN.1, and XBB.1.5. BA.4/5-containing bivalent vaccination significantly boosted nAb levels against both ancestral SARS-CoV-2 and Omicron subvariants. Participants with a history of SARS-CoV-2 infection had higher nAb titers against all examined strains than the infection-naïve group. NAb titers against BN.1 and XBB.1.5 were lower than those against the ancestral SARS-CoV-2 and BA.5 strains. These results suggest that COVID-19 vaccinations specifically targeting emerging Omicron subvariants, such as XBB.1.5, may be required to ensure better protection against SARS-CoV-2 infection, especially in high-risk groups.

키워드

과제정보

This work was supported by the Korea University Guro Hospital (Korea Research-Driven Hospital) grant (No. O2208131 and O2206871), Korea Basic Science Institute (National Research Facilities and Equipment Center) grant (No.2021R1A6C101C570) funded by the Ministry of Education, and National Research Foundation of Korea (NRF) grant (NRF-2022M3A9I2017241) funded by the Ministry of Science and ICT, Republic of Korea.

참고문헌

  1. World Health Organization. Tracking SARS-CoV-2 variants [Internet]. Available at: https://www.who.int/activities/tracking-SARS-CoV-2-variants [accessed on 28 June 2023].
  2. Liu L, Iketani S, Guo Y, Chan JF, Wang M, Liu L, Luo Y, Chu H, Huang Y, Nair MS, et al. Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2. Nature 2022;602:676-681.  https://doi.org/10.1038/s41586-021-04388-0
  3. Collier AY, Miller J, Hachmann NP, McMahan K, Liu J, Bondzie EA, Gallup L, Rowe M, Schonberg E, Thai S, et al. Immunogenicity of BA.5 bivalent mRNA vaccine boosters. N Engl J Med 2023;388:565-567.  https://doi.org/10.1056/NEJMc2213948
  4. Chalkias S, Harper C, Vrbicky K, Walsh SR, Essink B, Brosz A, McGhee N, Tomassini JE, Chen X, Chang Y, et al. A bivalent Omicron-containing booster vaccine against COVID-19. N Engl J Med 2022;387:1279-1291.  https://doi.org/10.1056/NEJMoa2208343
  5. Korea Disease Control and Prevention Agency. Press release: Jun 21, 2023 [Internet]. Available at: https://www.kdca.go.kr/filepath/boardSyview.es?bid=0015&list_no=722804&seq=2 [accessed on 28 June 2023].
  6. Korea Disease Control and Prevention Agency. Press release: Feb 15, 2023 [Internet]. Available at: https://www.kdca.go.kr/filepath/boardSyview.es?bid=0015&list_no=721886&seq=2 [accessed on 28 June 2023].
  7. World Health Organization. TAG-VE statement on Omicron sublineages BQ.1 and XBB [Internet]. Available at: https://www.who.int/news/item/27-10-2022-tag-ve-statement-on-omicron-sublineages-bq.1-and-xbb [accessed on 13 June 2023].
  8. Centers for Disease Control and Prevention. COVID data tracker: variant proportions [Internet]. Available at: https://covid.cdc.gov/covid-data-tracker/#variant-proportions [accessed on 13 June 2023].
  9. World Health Organization. Statement on the antigen composition of COVID-19 vaccines [Internet]. Available at: https://www.who.int/news/item/18-05-2023-statement-on-the-antigen-composition-ofcovid-19-vaccines [accessed on 13 June 2023].
  10. Food and Drug Administration. Updated COVID-19 vaccines for use in the United States beginning in fall 2023 [Internet]. Available at: https://www.fda.gov/vaccines-blood-biologics/updated-covid-19-vaccinesuse-united-states-beginning-fall-2023?source=email [accessed on 17 June 2023].
  11. Sun D, Hsu A, Bogardus L, Rubinstein LJ, Antonello JM, Gurney KB, Whiteman MC, Dellatore S. Development and qualification of a fast, high-throughput and robust imaging-based neutralization assay for respiratory syncytial virus. J Immunol Methods 2021;494:113054. 
  12. Whiteman MC, Bogardus L, Giacone DG, Rubinstein LJ, Antonello JM, Sun D, Daijogo S, Gurney KB. Virus reduction neutralization test: a single-cell imaging high-throughput virus neutralization assay for dengue. Am J Trop Med Hyg 2018;99:1430-1439.  https://doi.org/10.4269/ajtmh.17-0948
  13. Grist NR, Bell EJ, Ross CA. Diagnostic methods in clinical virology, 2nd ed. Philadelphia, PA: J. B. Lippincott; 1974.
  14. Cov-Lineages. Lineage list [Internet]. Available at: https://cov-lineages.org/lineage_list.html [accessed on 16 June 2023].
  15. Cao Y, Jian F, Wang J, Yu Y, Song W, Yisimayi A, Wang J, An R, Chen X, Zhang N, et al. Imprinted SARS-CoV-2 humoral immunity induces convergent Omicron RBD evolution. Nature 2023;614:521-529. 
  16. Liu Y, Wang Z, Zhuang X, Zhang S, Chen Z, Zou Y, Sheng J, Li T, Tai W, Yu J, et al. Inactivated vaccine-elicited potent antibodies can broadly neutralize SARS-CoV-2 circulating variants. Nat Commun 2023;14:2179.
  17. Liu S, Liang Z, Nie J, Gao WB, Li X, Zhang L, Yu Y, Wang Y, Huang W. Sera from breakthrough infections with SARS-CoV-2 BA.5 or BF.7 showed lower neutralization activity against XBB.1.5 and CH.1.1. Emerg Microbes Infect 2023;12:2225638. 
  18. Wang Q, Iketani S, Li Z, Liu L, Guo Y, Huang Y, Bowen AD, Liu M, Wang M, Yu J, et al. Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants. Cell 2023;186:279-286.e8.  https://doi.org/10.1016/j.cell.2022.12.018
  19. Miller J, Hachmann NP, Collier AY, Lasrado N, Mazurek CR, Patio RC, Powers O, Surve N, Theiler J, Korber B, et al. Substantial neutralization escape by SARS-CoV-2 Omicron variants BQ.1.1 and XBB.1. N Engl J Med 2023;388:662-664.  https://doi.org/10.1056/NEJMc2214314
  20. Zou J, Kurhade C, Patel S, Kitchin N, Tompkins K, Cutler M, Cooper D, Yang Q, Cai H, Muik A, et al. Neutralization of BA.4-BA.5, BA.4.6, BA.2.75.2, BQ.1.1, and XBB.1 with bivalent vaccine. N Engl J Med 2023;388:854-857. 
  21. Davis-Gardner ME, Lai L, Wali B, Samaha H, Solis D, Lee M, Porter-Morrison A, Hentenaar IT, Yamamoto F, Godbole S, et al. Neutralization against BA.2.75.2, BQ.1.1, and XBB from mRNA bivalent booster. N Engl J Med 2023;388:183-185.  https://doi.org/10.1056/NEJMc2214293
  22. Korea Disease Control and Prevention Agency. Neutralizing antibody against omicron subvariants (BA.1, BA.1.1, and BA.2). Public Health Wkly Rep 2022;15:1460-1462.
  23. Kurhade C, Zou J, Xia H, Liu M, Chang HC, Ren P, Xie X, Shi PY. Low neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1 and XBB.1 by parental mRNA vaccine or a BA.5 bivalent booster. Nat Med 2023;29:344-347.  https://doi.org/10.1038/s41591-022-02162-x
  24. Lasrado N, Collier AY, Miller J, Hachmann NP, Liu J, Sciacca M, Wu C, Anand T, Bondzie EA, Fisher JL, et al. Waning immunity against XBB.1.5 following bivalent mRNA boosters. Preprint at https://www.biorxiv.org/content/10.1101/2023.01.22.525079 (2023). 
  25. Wang Q, Bowen A, Tam AR, Valdez R, Stoneman E, Mellis IA, Gordon A, Liu L, Ho DD. SARS-CoV-2 neutralising antibodies after bivalent versus monovalent booster. Lancet Infect Dis 2023;23:527-528.  https://doi.org/10.1016/S1473-3099(23)00181-0
  26. Branche AR, Rouphael NG, Diemert DJ, Falsey AR, Losada C, Baden LR, Frey SE, Whitaker JA, Little SJ, Anderson EJ, et al. Comparison of bivalent and monovalent SARS-CoV-2 variant vaccines: the phase 2 randomized open-label COVAIL trial. Nat Med 2023;29:2334-2346.  https://doi.org/10.1038/s41591-023-02503-4
  27. Cohen KW, Linderman SL, Moodie Z, Czartoski J, Lai L, Mantus G, Norwood C, Nyhoff LE, Edara VV, Floyd K, et al. Longitudinal analysis shows durable and broad immune memory after SARS-CoV-2 infection with persisting antibody responses and memory B and T cells. Cell Rep Med 2021;2:100354. 
  28. Traut CC, Blankson JN. Bivalent mRNA vaccine-elicited SARS-CoV-2 specific T cells recognise the omicron XBB sublineage. Lancet Microbe 2023;4:e388. 
  29. Park K, Choi SJ, Shin EC. Omicron subvariants, including BA.4 and BA.5, substantially preserve T cell epitopes of ancestral SARS-CoV-2. Immune Netw 2022;22:e29. 
  30. Choi SJ, Kim DU, Noh JY, Kim S, Park SH, Jeong HW, Shin EC. T cell epitopes in SARS-CoV-2 proteins are substantially conserved in the Omicron variant. Cell Mol Immunol 2022;19:447-448. https://doi.org/10.1038/s41423-022-00838-5